معرفی
Dr. Ulf Eriksson is a Professor of Vascular Biochemistry at the Department of Medical Biochemistry and Biophysics, Karolinska Institutet. His research focuses on growth factor-regulated endothelial cell functions, with emphasis on vascular biology in metabolic and CNS diseases. He leads the Vascular Functions in Metabolic and CNS Diseases group.
Affiliations:
- Professor, Department of Medical Biochemistry and Biophysics
- Member of Karolinska Institutet’s research community
Research Interests:
Dr. Eriksson’s work centers on understanding the role of vascular endothelial growth factors (VEGF) and platelet-derived growth factors (PDGF) in diseases such as diabetic kidney disease, stroke, cancer, and fibrosis. Key areas include:
- Lipotoxicity in renal and hepatic disorders
- VEGF-B and PDGF signaling pathways
- Therapeutic interventions targeting vascular dysfunction
- Metabolic aspects of cancer and cachexia
Recent Research Trends: Articles highlight advancements in understanding VEGF-B’s role in adipose-kidney axis lipotoxicity, PDGFRα inhibition in stroke recovery, and anti-VEGF-B antibodies in tumor therapy. His work bridges basic science and translational medicine, aiming to develop novel treatments for metabolic and vascular diseases.
Grants & Funding:
- Swedish Cancer Society (multiple grants targeting liver cancer and cachexia)
- Novo Nordisk Foundation (VEGF-B in diabetic complications)
- Swedish Research Council (vascular biology and stroke projects)
Labs/Teams: The Ulf Eriksson group investigates metabolic and CNS disease mechanisms, with a focus on vascular dysfunction and growth factor signaling. Collaborations include drug development for stroke, fibrosis, and cancer.
